Discriminatory roles for D1 and D2 dopamine receptor subtypes in the in vivo control of neostriatal cyclic GMP.

[1]  O. H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.

[2]  B. J. Winer.  Statistical Principles in Experimental Design , 1992 .

[3]  P. Greengard,et al.  Dopamine-sensitive adenylate cyclase in caudate nucleus of rat brain, and its similarity to the "dopamine receptor". , 1972, Proceedings of the National Academy of Sciences of the United States of America.

[4]  M. Trabucchi,et al.  Focussed microwave radiation: a technique to minimize post mortem changes of cyclic nucleotides, dopa and choline and to preserve brain morphology. , 1974, Neuropharmacology.

[5]  A. Guidotti,et al.  Pharmacologically induced changes in the 3':5'-cyclic guanosine monophosphate content of rat cerebellar cortex: difference between apomorphine, haloperidol and harmaline. , 1977, The Journal of pharmacology and experimental therapeutics.

[6]  J. Hyttel,et al.  Effects of neuroleptics on 3H-haloperidol and 3H-cis(Z)-flupenthixol binding and on adenylate cyclase activity in vitro. , 1978, Life sciences.

[7]  R. George,et al.  Subcellular localization of dopamine-sensitive adenylate cyclase and dopamine receptor binding activities. , 1978, Life sciences.

[8]  H. Sarau,et al.  The central effects of a novel dopamine agonist. , 1978, European journal of pharmacology.

[9]  L. Iversen,et al.  Muscarinic cholinergic receptors in rat corpus striatum and regulation of guanosine cyclic 3',5'-monophosphate. , 1978, Molecular pharmacology.

[10]  J. Kebabian,et al.  Multiple receptors for dopamine , 1979, Nature.

[11]  E. Krebs,et al.  Protein phosphorylation catalyzed by cyclic AMP-dependent and cyclic GMP-dependent protein kinases. , 1980, Annual review of pharmacology and toxicology.

[12]  J. Rabey,et al.  Stimulation of pre- and postsynaptic dopamine receptors by an ergoline and by a partial ergoline , 1981, Brain Research.

[13]  J. C. Stoof,et al.  Opposing roles for D-1 and D-2 dopamine receptors in efflux of cyclic AMP from rat neostriatum , 1981, Nature.

[14]  T. Bártfai,et al.  8-Br-cyclic GMP mimics activation of muscarinic autoreceptor and inhibits acetylcholine release from rat hippocampal slices , 1981, Brain Research.

[15]  J. Kebabian,et al.  Evidence that LY-141865 specifically stimulates the D-2 dopamine receptor , 1981, Nature.

[16]  U. Walter.  Distribution of cyclic-GMP-dependent protein kinase in various rat tissues and cell lines determined by a sensitive and specific radioimmunoassay. , 2005, European journal of biochemistry.

[17]  P. Wood,et al.  Antagonists of excitatory amino acids and cyclic guanosine monophosphate in cerebellum , 1982, Neuropharmacology.

[18]  R. Mashal,et al.  Preferential inhibition of ligand binding to calf striatal dopamine D1 receptors by SCH 23390 , 1983, Neuropharmacology.

[19]  A. Barnett,et al.  SCH 23390, a potential benzazepine antipsychotic with unique interactions on dopaminergic systems. , 1983, The Journal of pharmacology and experimental therapeutics.

[20]  P. Greengard,et al.  DARPP-32, a dopamine- and adenosine 3':5'-monophosphate-regulated neuronal phosphoprotein. II. Comparison of the kinetics of phosphorylation of DARPP-32 and phosphatase inhibitor 1. , 1984, The Journal of biological chemistry.

[21]  R. Mailman,et al.  SCH-23390: a selective D1 dopamine antagonist with potent D2 behavioral actions. , 1984, European journal of pharmacology.

[22]  J. Larsen,et al.  Pharmacological effects of a specific dopamine D-1 antagonist SCH 23390 in comparison with neuroleptics. , 1984, Life sciences.

[23]  M. Olianas,et al.  Characterization of dopamine receptors mediating inhibition of adenylate cyclase activity in rat striatum. , 1985, Molecular pharmacology.

[24]  C. Saller,et al.  D-1 and D-2 dopamine receptor blockade: interactive effects in vitro and in vivo. , 1986, The Journal of pharmacology and experimental therapeutics.

[25]  C. Altar,et al.  Modulation of In Vivo Dopamine Release by D2 but Not D1 Receptor Agonists and Antagonists , 1987, Journal of neurochemistry.

[26]  R. Roskoski,et al.  Phosphorylation of Tyrosine Hydroxylase by Cyclic GMP‐Dependent Protein Kinase , 1987, Journal of neurochemistry.

[27]  R. Hohlweg,et al.  Thienopyridine derivatives identified as the first selective, full efficacy, dopamine D1 receptor agonists. , 1987, European journal of pharmacology.

[28]  C. Altar,et al.  Dopamine autoreceptor agonists including CGS 15855A decrease dopamine release and metabolism in mouse brain. , 1987, European journal of pharmacology.

[29]  M. Raiteri,et al.  Is the muscarinic receptor that mediates potentiation of dopamine release negatively coupled to the cyclic GMP system? , 1987, Journal of neuroscience research.

[30]  M. Olianas,et al.  Pharmacological and biochemical characterization of dopamine receptors mediating stimulation of a high affinity GTPase in rat striatum. , 1987, Biochemical pharmacology.

[31]  W. J. Thompson,et al.  Purification and partial characterization of membrane-associated type II (cGMP-activatable) cyclic nucleotide phosphodiesterase from rabbit brain , 1988 .

[32]  T. Skarsfeldt,et al.  SCH 23390--a selective dopamine D-1 receptor antagonist with putative 5-HT1 receptor agonistic activity. , 1988, European journal of pharmacology.

[33]  Positive interaction between alpha-1 adrenergic and dopamine-2 receptors in locomotor activity of normo and supersensitive mice. , 1989, Life sciences.